Roche sees positive results for new multiple sclerosis drug in late-stage trials

Please subscribe to IBJ to decode this article.

esoo shsraya s s oat asas atatmSkieelmeeyew tp mrt-eho wsdnmafo hhtrttttnld oun.r icntrenshlSthymclpmrtc rareecnteaeciaiuadg oan eiataeolRiromp ipehoclsslncga trt u t he peaxo stuoiiaaltra upps'fiieern pedntu atsenirg ls a im iw

susw runbaiedil t ni, wgrsoiityh ei- nfaenikneaeod-Pc oas nbeaGrdsdD nhoeey cai rmly spwnur rr an de,eleep v.fmdfbhrsc liIoOdohpAohR2padesuaeicrailtemirldaRcsheBeinire ngsa desryv oids o coM t astvcotiPihs1n i ir ’ i,tnpaoporohn eof topto etesltrucuiee c watp s Shb lboskRmlrne,sor cssscegghi%

amcolb tdtioyeh elvex o oPnSltf rmnem m U h i1i% ap0. imngvhip,sasP causrMlp,otlttomeieeAt d aikleolta aeesfm s1sp thhaeeeoduhtiwnfi ngtois tnnioeeSp tr laleiiros

ihceax d i,ewcn errtpi enrroeoCpsoetectsal aofoievw-sn i nudmapr op tncif id n eiufoeeigcpirgrd sool aetitioettl kl c elu lanti iimt , hsl iosslIpebimltseea sha,np.i g eh isi e nmsir dre ivmsrsctagpgmecptlfs hnocetowo ntlsoyhpinehlmo-m Cloourtch entysierdel mglmoeimtstoef

r veseirr rSyipo Philni h7o n.t infireytt rx pn ri ii aueeUmS1TtdePoo bp2 geeiando a nedusierppA ar.Mea v u eg .eDOdcociatadbos0tenfnlrceae1rynsFsnrndr ibme otnsisihesn irsstemd.ic Rul e0dt

ln rc ri“oor f ispt dfctnghau cnr ba tcsfPn seogievteSvorn Obo ey ed”i rr bi ird eeFse akrclutpirv btrmt tamri n aleiesGiiCreiPtnyafnnpiactmyruhLlriitig nebhh clyhcoPemsuwn neip Mptdtrie tfiert eca nsoRtoae.mienan u e,ciuSpasMen asrtMi oyeeiaeliliehuag fie ahedafnrs oi,tlvseasde n grdoddeesnsitnnsefaaPe

pts 91uli rndileiciichetshatjtt n a on ge hheutsleetno v aeb s2aniuipc nea nnirifyf c bodehos isensrsOnk iut cudvnnee deiaem htteuo .aceImo e O vr4snleirtaaeat oltypbyeeI ast.t tw 2hek e yancbsa8 rsabca opsldatirfvir irtehe a r acfciseiafPraomeah wdtnblnsIh tpenwngnoa pwtrpateeiboei ooelvu5teialem erael0 r r eoalnn tdv ne dttfslsd bwe v,t nhpan ui I,sreTu aeurse

e eoy lbf nld-a diat seeliosaal ntsa i temi tleaTes austuhfeo.eliipfltrmspbeugcrnnas prdhnnya aeiosttrptmt tannochi tsot

r anbilaicstcohitw iapetcho stodio iv yo aedfosalrhI ft8ntoeeurmeDs4 lihol yrtoi gat c hcoe heh i ieefPresy il a, Ia oRugnbalsno, 0rim rsniinsprf am hrtambhstel n oaonal0atit.fsrupt waIR eip lepf,sln tIen

y ia ein sdtheo ,hiopm lona:igrnt/nlr ifsttpc d n s"dtnRnI0o-sainnca ltd ubu iafn icutdediip/aic<$bii lc- joh-r - atih>tpsta9 ld5s v-5dwtpcoetbiea rj5 sd-aa.wet/vra0ea"een-tedhssil/ooodl /ifdwasdyyb ntodig nae--tsadaha-ov ossasehsoR sorpHm= fvt. aeem-1ens0moi-geo lxjt1dr5.ueot

neehainahcUvtbfte soaoepwp’inh emsd"ninf ldioiam-lliaeedyddnsacmanarAvtosismoils-fat hlcxies-il epsp/c,-deue sinna t nlstcao r ret ttrohiasoi sta/ pt=td0soipl i-dti rn$ nti g m teDpnh.eee rN t iat ad:-aprsthtvwens- enarneiSoontraewnfp-so/om b nfts hir //o nsrs ocwueraRtkown jn5icus.-t-gtttvoyh,eoen a ei peeeiaRcpstspi>winhn